Global industry leaders to address key trends in bioscience industry at Biotech 2009

NewsGuard 100/100 Score

Biotech 2009 (www.biotech2009.org) will bring together globally-recognized industry leaders to address key trends and topics relevant to the growth and advancement of the tri-state region’s bioscience industry.

Throughout the two-day event, more than 100 speakers, including 44 C-level executives, will discuss topics on key financial, scientific, business, and regulatory issues that are impacting the bioscience industry. This industry is integral to the economy of the tri-state region and the sessions at Biotech 2009 will address the key trends that have, and will continue, to affect the bioscience industry in this region.

Highlighted by keynotes from David Holveck, president & CEO of Endo Pharmaceuticals and Fred Hassan, chairman and CEO of Schering-Plough, Biotech 2009 will provide many interview opportunities for reporters who cover a variety of topics including business, finance, health, and science. This annual bioscience symposium is the largest such conference held in the region. Complimentary registration is available for credentialed members of the news media by e-mailing [email protected].

For business and finance reporters:

  • 44 C-level executives will speak at the conference including 27 CEOs, 7 CFOs, 7 CSOs, 1 CLO, 1 CCO, and 1 CTO.
  • Keynote speakers:
    • David Holveck, president & CEO of Endo Pharmaceuticals, will focus on the challenge of balancing growth and innovation in the rapidly evolving health care landscape (November 16 dinner).
    • Fred Hassan, chairman & CEO of Schering-Plough will engage in an intimate "fireside chat" on the theme "Leadership in a Time of Change: The Next 10 Years in Biotech" (November 17 lunch).
  • A plenary session focused on the past, present, and future state of the biotechnology industry on November 16.
  • Company presentations on November 16 featuring a diverse group of 37 bioscience companies from throughout the Mid-Atlantic region and beyond.
  • A Growth Strategies track on November 16 with sessions on the virtual business model, creative partnering, and developing value for your exit strategy.
  • A Regulatory track on November 16 with sessions on biosimilars, the FDA Amendments Act, and FDA/industry interactions while preparing for a pandemic.
  • A Finance track on November 17 with topics such as navigating the capital markets, cash preservation strategies, and creative financing transactions.
  • A Hot Topics in Business track on November 17 featuring sessions on the redefined role of venture capitalists, impact of health care reform, and building value in a development-stage company.

For health and science reporters:

  • A Drug Delivery, Device, and Diagnostics track on November 16 with sessions on the role of diagnostics in bioscience technology and health care, new trends in drug delivery, and advancements for the diagnosis and treatment of neurological disorders.
  • A Hot Topics in Science track on November 17 with topics on immunotherapeutics, regenerative medicine, and mitochondrial targets.
  • An Innovation Corridor featuring more than 50 scientific posters from some of the region’s most innovative young companies and research institutions.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
LabVantage celebrates customer success with record number of software deployments in FY 2024